A synthetic hormone with anabolic and androgenic properties.
Anavar, Lonavar, Oxandrin, Vasorome, Provitar, 53-39-4
(1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one
InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1
QSLJIVKCVHQPLV-PEMPUTJUSA-N
CC12CCC3C(C1CCC2(C)O)CCC4C3(COC(=O)C4)C
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C
7H6TM3CT4L
Anavar, Lonavar, Oxandrin, Vasorome, Provitar, 53-39-4, Ossandrolone [dcit], Oxandrolonum, Oxandrolona, Oxandrolonum [inn-latin], Oxandrolona [inn-spanish], Protivar, Sc 11585, Sc-11585, Oxandrolone Ciii, (1s,3as,3br,5as,9as,9bs,11as)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one, (4as,4bs,6as,7s,9as,9br,11as)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1h)-one, 7h6tm3ct4l, Chebi:7820, Nsc-67068, Ossandrolone, Oxandrin (tn), 8075 C. B., Hsdb 3373, Einecs 200-172-9, Nsc 67068, Unii-7h6tm3ct4l, 8075 Cb, 17beta-hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one, Oxandrolone (jan/usp/inn), 17beta-hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one, Oxandrin;anavar, 2-oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5alpha,17beta)-, 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one, Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1h-benz(e)indene-7-acetic Acid Delta-lactone, Oxandrolone [usan:usp:inn:ban:jan], 2-oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-, 8075 C.b., Oxandrolone [mi], Oxandrolone [inn], Oxandrolone [jan], Oxandrolone [hsdb], Oxandrolone [usan], Oxandrolone [vandf], Oxandrolone [mart.], Oxandrolone [who-dd], 17.beta.-hydroxy-17-methyl-2-oxa-5.alpha.-androstan-3-one, Schembl148881, Gtpl7092, 2-oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5.alpha.,17.beta.)-, Chembl1200436, Dtxsid8023399, Oxandrolone, >=98% (hplc), Oxandrolone [orange Book], Oxandrolone Ciii [usp-rs], 2-oxa-5-alpha-androstan-3-one, 17-beta-hydroxy-17-methyl-, Hms3712e22, Oxandrolone [usp Monograph], Hy-b0707, Zinc3813047, 2-oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-, Akos025401400, Ccg-220110, Db00621, Ac-14975, C07346, D00462, Ab01559948-01, 198o944, Q420859, Sr-01000872645, Sr-01000872645-1, W-105740, 17alpha-methyl-17beta-hydroxy-2-oxa-5alpha-androstan-3-one, (1s,2s,7s,10r,11s,14s,15s)-14-hydroxy-2,14,15-trimethyl-4-oxatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-one
2005-06-24
Oxandrolone is indicated in conditions such as chronic infections, extensive surgery, (corticosteroid-induced myopathy, decubitus ulcers, burns, /NOT included in US product labeling/) or severe trauma, which require reversal of catabolic processes or protein-sparing effects. /This agent is/ ... adjunct to, and not replacement for, conventional treatment of these disorders. /Included in US product labeling/
Oxandrolone is used in the treatment of the short stature that accompanies Turner's syndrome (gonadal dysgenesis in females). Although the therapy is controversial, recent experimental reports seem to indicate that oxandrolone may be as effective as growth hormone and that oxandrolone may increase the efficacy of growth hormone therapy. /NOT included in US product labeling/
Anabolic steroids may be used in children as an adjunct in the treatment of growth failure caused by pituitary growth hormone (GH) deficiency (pituitary dwarfism) or if the response to human growth hormone administration is inadequate. /Anabolic steroids; NOT included in US product labeling/
Peliosis hepatis, a condition in which liver and sometimes splenic tissue is replaced with blood-filed cysts, has occurred in patients receiving androgenic anabolic steroids. These cysts are sometimes present with minimal hepatic dysfunction and have been associated with liver failure. They are often not recognized until life-threatening liver failure or intro-abdominal hemorrhage develops. Withdrawal of drug usually results in complete disappearance of lesions. /Anabolic steroids/
Liver cell tumors: Most often these tumors are benign and androgen-dependent, but fatal malignant tumors have occurred. Withdrawal of drug often results in regression or cessation of tumor progression. However, hepatic tumors associated with androgens or anabolic steroids are much more vascular than other hepatic tumors and may be silent until life-threatening intra-abdominal hemorhage develops. /Anabolic steroids/
Use of anabolic steroids by athletes is not recommended. Objective evidence is conflicting and inconclusive as to whether these medications significantly increase athletic performance by increasing muscle strength. Weight gains reported by athletes are due in part to fluid retention, which is a potentially hazardous side effect of anabolic steroid therapy. The risk of other unwanted effects, such as testicular atrophy and suppression of spermatogenesis in males; menstrual disturbances and virilization, such as deepening of voice, development of acne, and unnatural growth of body hair in females; peliosis hepatis or other hepatotoxicity; and hepatic cancer outweigh and possible benefit received from anabolic steroids and make their use in athletes inappropriate. /Anabolic steroids/
Anabolic steroids are not recommended for use during pregnancy, since studies in animals have shown that anabolic steroids cause masculinization of the fetus. Risk-benefit must be carefully considered. /Anabolic steroids/
Use to promote weight gain after weight loss following extensive surgery.
Oxandrolone is an anabolic steroids indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis. Anabolic steroids are synthetic derivatives of testosterone.
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.
These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power.
A - Alimentary tract and metabolism
A14 - Anabolic agents for systemic use
A14A - Anabolic steroids
A14AA - Androstan derivatives
A14AA08 - Oxandrolone
It is not known whether anabolic steroids are distributed into breast milk. /Anabolic steroids/
Renal
The metabolism of 17 alpha-methyl-17 beta-hydroxy-2-oxa-5 alpha-androstan-3-one (oxandrolone) in man has been investigated by gas chromatography/mass spectrometry. After oral administration of a 10 mg dose to man, five metabolites were detected in the free fraction of the urinary samples. Oxandrolone, the major compound excreted in urine, was detected within 72 hr after administration. During this period 35.8 and 8.4% of the administered dose was excreted as unchanged oxandrolone and 17-epioxandrolone, respectively. In addition, minute amounts of 16 alpha- and 16 beta-hydroxyoxandrolone and a delta-hydroxy acid resulting from the hydrolysis of the lactone group of oxandrolone were detected in the urine samples 8-60 hr after administration.
0.55 hours (1st phage), 9 hours (2nd phase)
Biphasic: 1st phase - 0.55 hours. 2nd phase - 9 hours.
Oxandrolones interact with androgen receptors in target tissues.
Reverses catabolic processes and negative nitrogen balance by promoting protein anabolism and stimulating appetite if there is concurrently a proper intake of calories and proteins. /Anabolic steroids/
There was abs decrease in total serum cholesterol and redistribution of cholesterol, such that post-treatment low-density lipoprotein carried less cholesterol and high-density lipoprotein more cholesterol on percentage basis than found in pre-treatment values with oxandrolone.
